Regulatory

  1. Scott Gottlieb: The Future Of The CGT Regulatory Paradigm 2/1/2022

    Though Dr. Gottlieb has become one of the most trusted voices through the COVID pandemic, I wanted to hear how his thoughts on the advanced therapies development paradigm have evolved in the past few years, and how he sees the world of CGT CMC changing in the future.

  2. FDA Releases Draft Guidance On Use Of Real-World Evidence For Drug & Biological Products 1/19/2022

    The FDA has issued new draft guidance in its latest effort to clarify its expectations regarding the integration of real-world data (RWD) and real-world evidence (RWE) into clinical research, product approvals, and post-approval monitoring of drugs. You can submit public comments until March 3, 2022.

  3. Building The Right Team for FDA Approval of Your Innovative Medtech 1/17/2022

    Navigating the complexities of the FDA’s approval and regulatory process for medical devices can be daunting for all companies and particularly stressful for new technologies with disruptive innovation. However, the FDA is best regarded as a partner and not an obstruction. If your device development team does their homework, you'll have a successful product.

  4. Regulatory Intelligence: It's More Than Just Compliance 12/3/2021

    Every pharmaceutical company is under pressure to monitor the changes that are taking place in the regulated landscape and respond to them accordingly. Regulatory intelligence activities include collecting, evaluating, and analyzing various pieces of information to position your company for success.

  5. Can the FDA & CDC Recover from Recent Politics? 12/1/2021

    Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

  6. Marks Took On FDA Vaccine Leadership Position – What Happens Now? 11/2/2021

    Center for Biologics Evaluation and Research Director Dr. Peter Marks decided to temporarily take on the leadership of the Office of Vaccine Research and Review after both its director, Marion Gruber, and deputy director, Philip Krause, unexpectedly announced in late August their decisions to exit the FDA.

  7. Why Korea Is Now More Attractive To U.S. Biopharma 11/1/2021

    A quirk in Korea’s patent laws made it relatively difficult to secure patent protection for many drugs. That is, until this year.

  8. U.S. Biopharma Manufacturing: Not An Overhead Cost But A Value Center! 11/1/2021

    Jeff Baker, previously of the FDA, comments on what he sees as the shortcomings of the industry’s approach to biopharma manufacturing.

  9. AVROBIO's Geoff MacKay On Cell & Gene Scalability 10/4/2021

    Geoff MacKay, president and CEO of AVROBIO, talks with The Business of Biotech podcast about the scale up obstacles facing the cell and gene therapy space and how AVRO is working to tackle them.

  10. bluebird Bio's Scott Cleve On New Therapies, New Regulatory Approaches 10/4/2021

    bluebird bio's Scott Cleve sat down with The Business of Biotech podcast to talk about shifting regulatory standards and how pharmas can adapt how they engage with regulators.